Intervention not reported
Quality of life (Asthma Quality of Life Questionnaire, with 32 items, 0 to 7 points per item) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Asthma symptoms (different severity scores; change from baseline) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Asthma control (weekly number of attacks) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Forced expiratory volume in one second (change from baseline FEV1 (L)) · People with asthma (mostly mild or moderate)
1 finding from 1 review
Intervention not reported
Reduced asthma medication usage · People with asthma (mostly mild or moderate)
The intervention may leads to higher reduced asthma medication usage (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · People with asthma (mostly mild or moderate)
1 finding from 1 review
All‐cause mortality · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in all‐cause mortality compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Stroke · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in stroke (total) compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Total coronary heart disease · general population including those at moderate to high risk of CVD, mean age between 30 and 75
Systematic screening showed no clear difference in coronary heart disease (total) compared with no/opportunistic screening (low certainty).
1 finding from 1 review
Cholesterol mg/dL · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review
Systolic blood pressure · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review
Diastolic blood pressure · general population including those at moderate to high risk of CVD, mean age between 30 and 75
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Median (mean) time to use of rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Number of women requiring rescue medication · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose, and after 3 to 5 days · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose, and after 3 to 5 days · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Cognitive function · Apathy in people with mild‐to‐moderate Alzheimer's disease
2 findings from 1 review
Change in capacity for activities of daily living · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Physician rated global impression tests (no change or worse compared with baseline, measured using Global Impression of Change at 26 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to lower physician rated global impression tests (no change or worse compared… compared with placebo (moderate certainty).
1 finding from 1 review